Printed from https://ideas.repec.org/s/spr/pharme9.html
Content
May 2009, Volume 27, Issue 5
- 391-403 The Cost of Dementia in Europe
by Linus Jönsson & Anders Wimo - 405-419 Utility Assessment in Patients with Mental Disorders
by Hans-Helmut König & Oliver Günther & Matthias Angermeyer & Christiane Roick
April 2009, Volume 27, Issue 4
- 267-279 Economic and Human Costs of Restless Legs Syndrome
by Thomas Reinhold & Falk Müller-Riemenschneider & Stefan Willich & Bernd Brüggenjürgen - 281-297 Reviewing the Cost Effectiveness of Rotavirus Vaccination
by Joke Bilcke & Philippe Beutels - 313-327 Cost Effectiveness of Drug-Eluting Stents In Belgian Practice
by Mattias Neyt & Chris Laet & Annemieke Ridder & Hans Brabandt - 329-339 Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder
by Laura Pizzi & Amy Talati & Eric Gemmen & Naomi Dahl & Thomas Bunz & Peter Sand
March 2009, Volume 27, Issue 3
- 221-230 The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone
by Peter Lindgren & Martin Buxton & Thomas Kahan & Neil Poulter & Björn Dahlöf & Peter Sever & Hans Wedel & Bengt Jönsson - 231-245 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
by Lieven Annemans & Vanessa Rémy & James Oyee & Nathalie Largeron - 247-261 Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan
by Ataru Igarashi & Hiroki Takuma & Takashi Fukuda & Kiichiro Tsutani
February 2009, Volume 27, Issue 2
- 91-93 Controlling Cervical Cancer
by Maurizio Bonati & Silvio Garattini - 95-112 Neuropathic Pain
by Alec O’Connor - 127-147 Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
by Fawziah Marra & Karine Cloutier & Bridgette Oteng & Carlo Marra & Gina Ogilvie - 159-165 Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV
by Kit Simpson & Alvin Strassburger & Walter Jones & Birgitta Dietz & Rukmini Rajagopalan
January 2009, Volume 27, Issue 1
- 25-37 Statin Therapy in Rheumatoid Arthritis
by Nick Bansback & Roberta Ara & Sue Ward & Aslam Anis & Hyon Choi - 55-68 Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma
by Philippe Fagnoni & Noel Milpied & Samuel Limat & Eric Deconinck & Virginie Nerich & Charles Foussard & Philippe Colombat & Jean-Luc Harousseau & Marie-Christine Woronoff-Lemsi - 81-90 Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
by Ulf-G Gerdtham & Philip Clarke & Alison Hayes & Soffia Gudbjornsdottir
December 2008, Volume 26, Issue 12
- 1005-1017 Measuring US Pharmaceutical Industry R&D Spending
by Joseph Golec & John Vernon - 1019-1035 Management and Prevention of Diabetic Foot Ulcers and Infections
by Ivy Chow & Elkin Lemos & Thomas Einarson - 1045-1064 A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
by Alec O’Connor & Katia Noyes & Robert Holloway
November 2008, Volume 26, Issue 11
- 911-924 The Impact of Influenza on Working Days Lost
by Martin Keech & Paul Beardsworth - 925-935 A Review of Health-Utility Data for Osteoarthritis
by Hirsch Ruchlin & Ralph Insinga - 937-949 A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
by D. Spackman & David Veenstra - 951-967 Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
by Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler - 969-981 Escitalopram and Duloxetine in Major Depressive Disorder
by Alan Wade & José-Luis Fernández & Clément François & Karina Hansen & Natalya Danchenko & Nicolas Despiege
August 2008, Volume 26, Issue 8
- 649-659 Assessing the Impact of Global Price Interdependencies
by Anke Richter - 661-677 Conducting Discrete Choice Experiments to Inform Healthcare Decision Making
by Emily Lancsar & Jordan Louviere
July 2008, Volume 26, Issue 7
- 589-602 Future Drug Prices and Cost-Effectiveness Analyses
by Martin Hoyle - 603-616 Generic Entry, Reformulations and Promotion of SSRIs in the US
by Haiden Huskamp & Julie Donohue & Catherine Koss & Ernst Berndt & Richard Frank - 617-627 Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
by Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan
June 2008, Volume 26, Issue 6
- 447-462 Economic Burden of Heart Failure in the Elderly
by Lawrence Liao & Larry Allen & David Whellan - 513-536 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
by Dirk Mueller & Eva Weyler & Afschin Gandjour
April 2008, Volume 26, Issue 4
- 311-328 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis
by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut König
March 2008, Volume 26, Issue 3
- 191-215 Cost-Effectiveness Analyses of Vaccination Programmes
by Sun-Young Kim & Sue Goldie - 217-234 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
by Jeremy Chancellor & Samuel Aballéa & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant - 235-249 Community and Patient Values for Preventing Herpes Zoster
by Tracy Lieu & Ismael Ortega-Sanchez & G. Ray & Donna Rusinak & W. Yih & Peter Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa Prosser
January 2008, Volume 26, Issue 1
- 17-32 Cost-Effectiveness Analyses of Hepatitis A Vaccine
by Andrea Anonychuk & Andrea Tricco & Chris Bauch & Ba’ Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn - 33-44 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas
by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville - 57-73 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration
by Alan Cruess & Gergana Zlateva & Xiao Xu & Gièle Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas Goss
December 2007, Volume 25, Issue 12
- 995-996 When NICE Says No!
by Alan Haycox - 997-1006 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors
by Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro - 1007-1029 Recombinant Factor VIIa (Eptacog Alfa)
by Katherine Lyseng-Williamson & Greg Plosker - 1031-1053 Atorvastatin
by Greg Plosker & Katherine Lyseng-Williamson - 1055-1062 Economic Evidence at the Local Level
by Kees Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward - 1063-1082 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events
by Bart Heeg & Joep Damen & Ben Hout
November 2007, Volume 25, Issue 11
- 899-902 Warfarin Pharmacogenetics
by Dyfrig Hughes & Munir Pirmohamed - 903-911 It’s Time to Choose the Study Design!
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman - 913-933 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis
by Rachael Fleurence & Cynthia Iglesias & Jeanene Johnson - 963-977 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
by David Veenstra & Sean Sullivan & Lauren Clarke & Uche Iloeje & Eskinder Tafesse & Adrian Bisceglie & Kris Kowdley & Robert Gish
October 2007, Volume 25, Issue 10
- 807-816 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions
by Jeffrey Hoch & Carolyn Dewa - 829-841 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
by Laura Bojke & Edward Hornby & Mark Sculpher - 843-862 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
by Ya-Chen Shih & Nebiyou Bekele & Ying Xu - 863-879 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
by Sorrel Wolowacz & Neil Roskell & Steven Kelly & Fiona Maciver & Chris Brand - 881-897 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin
by Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer
September 2007, Volume 25, Issue 9
- 713-726 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children
by Lisa Prosser & James Hammitt & Ron Keren - 751-768 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus
by Andrew Shorr - 769-782 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
by Bart Heeg & Ron Peters & Marc Botteman & Ben Hout
July 2007, Volume 25, Issue 7
- 577-590 A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
by Ya-Chen Shih & Josephine Mauskopf & Rohit Borker - 605-618 Direct and Indirect Costs Attributable to Alcohol Consumption in Germany
by Alexander Konnopka & Hans-Helmut König
June 2007, Volume 25, Issue 6
- 467-479 A Systematic Review of Economic Evaluation Literature in Thailand
by Yot Teerawattananon & Steve Russell & Miranda Mugford - 481-496 Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs
by Theodore Darkow & Henry Henk & Simu Thomas & Weiwei Feng & Jean-Francois Baladi & George Goldberg & Alan Hatfield & Jorge Cortes
May 2007, Volume 25, Issue 5
- 365-384 Health Utilities Using the EQ-5D in Studies of Cancer
by A. Pickard & Caitlyn Wilke & Hsiang-Wen Lin & Andrew Lloyd - 385-396 The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)
by Peter Wahlqvist & Gordon Guyatt & David Armstrong & Alessio Degl’Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo Fallone & Lisa Tanser & Sander Zanten & Peggy Austin & Alan Barkun & Naoki Chiba & Holger Schünemann - 397-411 Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England
by Anthony Scott & Michela Tinelli & Christine Bond - 429-442 Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer
by J. Millar & Michael Millward
March 2007, Volume 25, Issue 3
- 209-221 Do Drugs Reduce Utilisation of Other Healthcare Resources?
by Pierre-Yves Crémieux & Pierre Ouellette & Patrick Petit - 223-237 Recombinant Erythropoietin for Chemotherapy-Related Anaemia
by Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher - 239-251 Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients
by Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore
February 2007, Volume 25, Issue 2
- 93-106 Measuring Preferences for Cost-Utility Analysis
by Christine McDonough & Anna Tosteson - 155-169 Acute/Subacute Herpes Zoster
by Ralph Insinga & Robbin Itzler & James Pellissier
January 2007, Volume 25, Issue 1
- 1-2 Letter From the Commissioner’s Office at the US FDA
by John Vernon - 3-6 Rates and Probabilities in Economic Modelling
by Rachael Fleurence & Christopher Hollenbeak - 7-24 Reducing the Societal Burden of Depression
by Julie Donohue & Harold Pincus - 25-37 Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
by Judith Bosmans & Oscar Brook & Hein Hout & Martine Bruijne & Hugo Nieuwenhuyse & Lex Bouter & Wim Stalman & Maurits Tulder - 39-54 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos - 55-71 Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children
by Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier - 73-88 Time Preferences for Health in Northern Tanzania
by Bjarne Robberstad & John Cairns
December 2006, Volume 24, Issue 12
- 1173-1177 Do Pharmacogenomic Tests Provide Value to Policy Makers?
by Ya-Chen Shih & Lajos Pusztai - 1179-1179 Letter From the Commissioner’s Office at the US FDA
by John Vernon - 1181-1197 Assessing Generalisability in Model-Based Economic Evaluation Studies
by Hege Urdahl & Andrea Manca & Mark Sculpher - 1199-1220 Generic Health-Related Quality-of-Life Assessment in Children and Adolescents
by Ulrike Ravens-Sieberer & Michael Erhart & Nora Wille & Ralf Wetzel & Jennifer Nickel & Monika Bullinger - 1221-1232 Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
by James Spalding & Joel Hay - 1233-1248 Association of Co-Morbidities with Prescribing Patterns and Cost Savings
by Wei Yu & Xinhua Ren & Austin Lee & Lawrence Herz & Yu-Hui Huang & Lewis Kazis - 1249-1272 Candesartan Cilexetil
by Greg Plosker & Susan Keam - 1273-1274 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
by Stuart Birks - 1275-1276 The Authors’ Reply
by J. Bos & M. Postma & L. Annemans
September 2006, Volume 24, Issue 9
- 833-836 US FDA Guidance
by Paul Kind - 837-844 Accuracy versus Transparency in Pharmacoeconomic Modelling
by David Eddy - 845-853 The Value of Thinly Spread QALYs
by Duncan Mortimer - 855-868 Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework
by Emma McIntosh - 869-890 Cost-of-Illness Studies
by Ebere Akobundu & Jing Ju & Lisa Blatt & C. Mullins - 891-902 Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003
by Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen - 903-915 Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia
by John Wlodarczyk & Leslie Cleland & Anne Keogh & Keith McNeil & Kate Perl & Robert Weintraub & Trevor Williams - 917-925 Missing Data Imputation in Quality-of-Life Assessment
by Ting Lin - 927-929 Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes
by Andrew Palmer & Craig Currie - 929-935 The Authors’ Reply
by Adrian Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-Blasco & Belen Martinez-Lage & Isabel Escolano & Gonzalo Paris
August 2006, Volume 24, Issue 8
- 743-750 Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension
by Michelle Orme & Annabel Boler - 751-765 A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
by Darren Clayson & Diane Wild & Paul Quarterman & Isabelle Duprat-Lomon & Maria Kubin & Stephen Coons - 797-814 Costs of Inflammatory Bowel Disease in Germany
by Renee Stark & Hans-Helmut König & Reiner Leidl - 815-830 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
by Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette
June 2006, Volume 24, Issue 6
- 523-535 Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy
by Cornelis Boersma & Jarir Atthobari & Ron Gansevoort & Lolkje Jong-Van den Berg & Paul Jong & Dick Zeeuw & Lieven Annemans & Maarten Postma - 537-548 Healthcare Rationing in Spain
by Rosa Rodríguez-Monguió & Fernando Villar - 549-558 The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
by George Carides & Shahnaz Shahinfar & Erik Dasbach & William Keane & William Gerth & Charles Alexander & William Herman & Barry Brenner - 559-569 The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status
by Jarmo Hahl & Helena Hämäläinen & Tuula Simell & Olli Simell - 571-591 Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients
by Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz - 593-607 Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients
by George Dranitsaris & Mark Vincent & Mark Crowther - 609-621 Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?
by Lee-Yee Chong & Oh-Moh Chay & Li Shu-Chuen - 623-625 Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease
by Nick Bosanquet & Andrew Yeates - 625-626 The Authors’ Reply
by Colin Green & Joanna Picot & Emma Loveman & Andrea Takeda & Jo Kirby & Andrew Clegg
April 2006, Volume 24, Issue 4
- 387-400 A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy
by Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson
March 2006, Volume 24, Issue 3
- 265-280 Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias
by Jerrold Hill & Howard Fillit & Simu Thomas & Sobin Chang - 281-292 Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
by Richard Milne & Kathy Heaton-Brown & Paul Hansen & David Thomas & Vernon Harvey & Alison Cubitt
December 2006, Volume 24, Issue 3
- 1-3 Medicaid Preferred Drug Lists: Cost Containment and Side Effects
by Alvin Headen - 5-25 The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003
by Frank Lichtenberg - 27-40 Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives?
by Jonathan Ketcham & Andrew Epstein - 41-53 Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods
by Alvin Headen & Neal Masia & Kirsten Axelsen - 55-63 Preferred Drug Lists and Medicaid Prescriptions
by Tamer Abdelgawad & Lisa Egbuonu-Davis - 65-78 Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence
by David Ridley & Kirsten Axelsen - 79-84 Per-patient-per-month Drug Costs in Medicare Part D Protected Classes
by Lisa Mucha & Neal Masia & Kirsten Axelsen
February 2006, Volume 24, Issue 2
- 171-191 The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia
by Rachael DiSantostefano & Andrea Biddle & John Lavelle - 193-205 Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries
by Antoine Lafuma & Antoine Brézin & Stefania Lopatriello & Klaus Hieke & Julia Hutchinson & Viviane Mimaud & Gilles Berdeaux
December 2006, Volume 24, Issue 2
- 1-3 Foreword
by Christopher-Paul Milne - 5-14 Health Reform in the US
by Robert Helms - 15-28 What Works and What Doesn’t Work Well in the US Healthcare System
by Harold Luft - 29-33 What an Informed Patient Means for the Future of Healthcare
by Ruth Parker - 35-54 The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine
by Desmond Sheridan & Jim Attridge - 55-57 Disease Management Programmes in Germany
by Stefan Felder - 59-68 Do Health-Related Labour Costs Weaken the Competitiveness of the Economy?
by Bertram Häussler & Thomas Ecker & Markus Schneider - 69-86 The Impact of Incremental Innovation in Biopharmaceuticals
by Ernst Berndt & Iain Cockburn & Karen Grépin - 87-94 Transatlantic Convergence with Respect to the Fourth Hurdle?
by Joshua Cohen - 95-99 Political Challenges for Healthcare Reform
by Lawrence Brown - 101-109 Lean Systems Approaches to Health Technology Assessment
by John Bridges - 111-119 Building a Competitive Insurance System
by Peter Zweifel - 121-122 Concluding Remarks
by Kenneth Kaitin
November 2006, Volume 24, Issue 1
- 1-3 Simulating the Real World of Antihyperglycaemic Therapies in Type 2 Diabetes
by Amanda Adler - 5-19 A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies
by Adrian Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart - 21-34 Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK
by Sophie Beale & Adrian Bagust & Arran Shearer & Alan Martin & Lisa Hulme - 35-48 Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany
by Arran Shearer & Adrian Bagust & Andreas Liebl & Oliver Schoeffski & Anita Goertz - 49-59 Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain
by Arran Shearer & Adrian Bagust & F. Ampudia-Blasco & Belén Martínez-Lage Álvarez & Isabel Pérez Escolano & Gonzalo París
December 2005, Volume 23, Issue 12
- 1193-1202 The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply
by Joseph DiMasi & Cherie Paquette - 1215-1227 Willingness to pay for inhaled insulin
by Hamid Sadri & Linda MacKeigan & Lawrence Leiter & Thomas Einarson
October 2005, Volume 23, Issue 10
- 995-1006 Pharmacological management of overactive bladder
by Denis Getsios & Wissam El-Hadi & Ingrid Caro & J. Caro - 1007-1020 The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden
by Peter Hertzman - 1057-1072 Eplerenone
by Katherine Croom & Greg Plosker
June 2005, Volume 23, Issue 6
- 543-566 The economics of topical immunomodulators for the treatment of atopic dermatitis
by William Abramovits & Mark Boguniewicz & Amy Paller & Diane Whitaker-Worth & Mary Prendergast & Michael Tokar & Kuo Tong - 619-637 Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
by Michael Spencer & Andrew Briggs & Ronald Grossman & Laureen Rance
October 2004, Volume 22, Issue 15
- 985-999 Economic Impact of Migraine and Other Episodic Headaches in France
by André Pradalier & Jean-Paul Auray & Abdelkader Hasnaoui & Kazem Alzahouri & Jean-François Dartigues & Gérard Duru & Patrick Henry & Michel Lantéri-Minet & Christian Lucas & Guy Chazot & Anne-François Gaudin
January 2003, Volume 21, Issue 1
- 1-11 Generic Clozapine
by Gordon Tse & Deborah Thompson & Ric Procyshyn - 13-38 Economic Evaluations of Varicella Vaccination Programmes
by Nancy Thiry & Philippe Beutels & Pierre Damme & Eddy Doorslaer - 39-48 Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
by Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour - 49-60 Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK
by Venanzio Vella - 61-74 Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting
by W. Simons
May 2001, Volume 19, Issue 5
- 449-468 Hip Fracture Prevention
by Peter Vestergaard & Lars Rejnmark & Leif Mosekilde - 483-495 The Lifetime Cost of Bipolar Disorder in the US
by Charles Begley & John Annegers & Alan Swann & Christopher Lewis & Sharon Coan & William Schnapp & Lynda Bryant-Comstock - 497-512 Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension
by Peter Schädlich & Josef Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz
April 2000, Volume 17, Issue 4
- 319-324 The Importance of Achieving Additional Drug Benefits at a Reasonable Cost
by Nick Freemantle & James Mason - 325-330 Cost Effectiveness of Combination HIV Therapy
by Richard Moore - 331-338 Economic Burden of Irritable Bowel Syndrome
by Michael Camilleri & Donald Williams - 339-349 Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio
by Anthony O’Hagan & John Stevens & Jacques Montmartin - 351-360 Potential Savings in the Cost of Caring for Alzheimer’s Disease
by A. Hauber & Ari Gnanasakthy & Edward Snyder & Mohan Bala & Anke Richter & Josephine Mauskopf - 361-370 Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy
by Mark Sculpher & Michael Palmer & Anne Heyes - 371-382 Initial Treatment Choice in Depression
by Eric Edgell & Timothy Hylan & JoLaine Draugalis & Stephen Coons - 383-389 Cost Analysis of the Treatment of Schizophrenia in the UK
by Stephen Almond & Owen O’Donnell - 391-401 Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia
by Amnon Sonnenberg
December 1998, Volume 14, Issue 6
- 597-601 Are Mental Health Services Losing Out in the US Under Managed Care?
by Dale Johnson - 603-611 Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs
by Theodore Wein & Susan Hickenbottom & Andrei Alexandrov - 613-627 A Review of Quality of Life in Alzheimer’s Disease
by Sam Salek & Melvyn Walker & Antony Bayer - 629-637 Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption
by Hind Hatoum & Sheldon Kong & Christopher Kania & Josephine Wong & Wallace Mendelson - 639-652 The Use and Cost of HIV Service Provision in England in 1996
by Eduard Beck & Keith Tolley & Amanda Power & Sundhiya Mandalia & Philippa Rutter & Junichi Izumi & Jeni Beecham & Alistair Gray & David Barlow & Philippa Easterbrook & Martin Fisher & John Innes & George Kinghorn & Bibhat Mandel & Anton Pozniak & Allan Tang & David Tomlinson & Ian Williams - 653-669 Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction
by Peter Schädlich & Eduard Huppertz & Josef Brecht - 671-684 Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
by Maureen Mölken & Eddy Doorslaer & M. Till - 685-690 Fosphenytoin
by Stephen Holliday & Paul Benfield & Greg Plosker - 691-708 Cyclosporin Microemulsion (Neoral®)†
by Allan Coukell & Greg Plosker - 709-709 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
by Linda MacKeigan - 710-711 The authors reply
by Sheila Hood & Lieven Annemans & Maureen Mölken - 711-712 Common Errors and Controversies in Pharmacoeconomic Analyses
by Javier Soto
June 1997, Volume 11, Issue 6
- 594-594 Erratum to Will Managed Care Work in Europe?
by E. Mossialos & P. Kanavos & B. Abel-Smith
March 1997, Volume 11, Issue 3
- 286-286 Erratum to Rational prescribing of antibacterials in ambulatory children
by JE Hoppe
February 1997, Volume 11, Issue 2
- 115-118 Economic Evaluation Techniques in Healthcare
by Alan Maynard - 119-125 The Role of the US Food and Drug Administration’s Patient Information Initiative in Cost-Effective Drug Therapy
by Stuart Nightingale & Thomas McGinnis - 126-138 The Economics of Osteoporosis and Its Prevention
by David Torgerson & David Reid - 139-158 The Economics of Pharmacotherapy for Diabetes Mellitus
by Bernardo Costa & Jaume Arroyo & Angels Sabaté - 159-168 Guidelines for Pharmacoeconomic Studies
by Joanna Siegel & George Torrance & Louise Russell & Bryan Luce & Milton Weinstein & Marthe Gold - 169-174 An Economic Evaluation of the Use of Granulocyte Colony-Stimulating Factor After Bone Marrow Transplantation in Children
by Nicholas Duncan & Margaret Hewetson & Ayad Atra & Gina Dick & Ross Pinkerton - 175-183 Differences in the Methodology and Data of Economic Evaluations of a Health Programme
by Xavier Badia & Gonzalo Nocea & Joan Rovira - 184-197 Terazosin
by Greg Plosker & Karen Goa